Preparation and Performance Study of COS/PEI@PolyI:C/OVA Nanocomposite Using the Blend System of Chitooligosaccharide and Polyethyleneimine as a Drug Carrier

Kai Zhang; Qian Sun; Xiaoyu Bai; Peng Liu; Zijian Lyu; Qiuhong Li; Aixiang Li

Macromolecular Research, Vol.29, No.11, 800-809, November, 2021

DOI10.1007/s13233-021-9089-1 Export Citation

Preparation and Performance Study of COS/PEI@PolyI:C/OVA Nanocomposite Using the Blend System of Chitooligosaccharide and Polyethyleneimine as a Drug Carrier

Kai Zhang, Qian Sun, Xiaoyu Bai, Peng Liu, Zijian Lyu, Qiuhong Li, and Aixiang Li^†

School of Material Science and Engineering, Shandong University of Technology, Zibo, 255049, P. R. China

E-mail:

The blending system of chitooligosaccharide (COS) and polyethyleneimine (PEI) was studied as a drug carrier for tumor treatment. Nanoparticles COS/ PEI-PolyI:C-OVA-x (CP-P-O-x) (x=1, 2, 3) were prepared by electrostatic self-assembly of COS and PEI with the immune enhancing drug PolyI:C and the mimic antigen ovalbumin (OVA) using different feeding methods. The results showed that the nanoparticle solution could be stable only when the concentration of the added PEI was above 5.0% w/w. PolyI:C could be coated well and protected from nuclease degradation. The OVA encapsulation efficiency was above 75%. The results of cell viability experiments showed that the blend of COS and PEI had low cytotoxicity. The CP-P-O-1 had a suitable particle size, which was easy to be absorbed and expressed by cells. The results of in vitro immunization showed that due to the addition of PolyI:C, whether OVA was loaded on the inside or on the surface, nanoparticles significantly promoted the secretion of cytokines mouse tumor necrosis factor α (TNF-α) and mouse interferon-γ (IFN-γ). The feeding method mainly had a greater impact on the morphology and size of the nanoparticles, and had little effect on solution stability, OVA encapsulation efficiency, binding ability with PolyI:C, resistance to nuclease degradation and immune performance. CP-P-O-x prepared by the blend system of COS and PEI will be a potential candidate for tumor treatment.

Keywords:chitooligosaccharide;polyethyleneimine;blending system;PolyI:C;nanoparticle

[References]

Sun L, Chen L, Li H, Int. Immunopharmacol., 67, 160 (2019)
Ribas A, Butterfield LH, Glaspy JA, Economou JS, J. Clin. Oncol., 21, 2415 (2003)
Smith DM, Simon JK, Baker JR, Nat. Rev. Immunol., 13, 592 (2013)
Hayat SMG, Darroudi M, J. Cell. Physiol., 234, 12530 (2019)
Huang C, Chen S, Zhang T, Li D, Huang Z, Huang J, Qin Y, Chen B, Cheng G, Ma F, Zhou M, Front. Immunol., 10, 1 (2019)
Duluc D, Tan F, Scotet M, Blanchard S, Fremaux I, Garo E, Horvat B, Eid P, Delneste Y, Jeannin P, Eur. J. Immunol., 39, 2877 (2009)
Li Y, Xu XL, Zhao D, Pan LN, Huang CW, Guo LG, Lu Q, Wang J, CNS Neurosci. Ther., 21, 905 (2015)
Zong C, Sun Y, Zhang N, Wang F, Li A, Li Q, Lyu Z, Macromol. Res., 27(8), 772 (2019)
Correia-Pinto JF, Csaba N, Schiller JT, Alonso MJ, Vaccines, 3, 730 (2015)
Phil L, Naveed M, Mohammad IS, Bo L, Bin D, Biomed. Pharmacother., 012, 438 (2018)
Kim SK, Park PJ, Yang HP, Han SS, Arzneimittel-Forschung, 51, 769 (2001)
Yang EJ, Kim JG, Kim JY, Kim SC, Lee NH, Hyun CG, Cent. Eur. J. Biol., 5, 95 (2010)
Huang X, Chen M, Wu H, Jiao Y, Zhou C, ACS Biomater. Sci. Eng., 6, 1614 (2020)
Chung MJ, Park JK, Park YI, Int. Immunopharmacol., 12, 453 (2012)
Su LY, Fang TY, Tseng WC, Biochem. Eng. J., 49, 21 (2010)
Ahn HH, Lee JH, Kim KS, Lee JY, Kim MS, Khang G, Lee IW, Lee HB, Biomaterials, 29, 2415 (2008)
Park H, Nichols JW, Kang HC, Bae YH, Polym. Adv. Technol., 25, 545 (2014)
Duo X, Bai L, Wang J, Ji H, Guo J, Ren X, Shi C, Xia S, Zhang W, Feng Y, Polym. Adv. Technol., 30, 2567 (2019)
Gao JQ, Zhao QQ, Lv TF, Shuai WP, Zhou J, Tang GP, Liang WQ, Tabata Y, Hu YL, Int. J. Pharm., 387, 286 (2010)
Bao X, Wang W, Wang C, Wang Y, Zhou J, Ding Y, Biomaterials, 35, 8450 (2014)
Sugiura H, Okazaki N, Sugiura T, Honda H, Okochi M, Biochem. Eng. J., 87, 8 (2014)
Liu K, Chen S, Chen H, Tong P, Gao J, Int. J. Biol. Macromol., 107, 2057 (2018)
Li Z, Kuang H, Yang J, Hu J, Ding B, Sun W, Luo Y, Sci. Rep., 10, 1 (2020)
Chuck AS, Clarke MF, Palsson BO, Gene Therapy, 1534, 1527 (1996)
Liu Y, Tan J, Thomas A, Ou-Yang D, Muzykantov VR, Ther. Deliv., 3, 181 (2012)
Li Y, Lian Y, Zhang LT, Aldousari SM, Hedia HS, Asiri SA, Liu WK, Interface Focus, 6, 0086 (2015)
Torchilin VP, Nat. Rev. Drug Discov., 4, 145 (2005)
Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH, Int. J. Mol. Sci., 22, 1 (2021)
Lee CC, Chiu CC, Liao WT, Wu PF, Chen YT, Huang KC, Chou YT, Wen ZH, Wang HM, Biochem. Eng. J., 78, 101 (2013)

[1] Sun L, Chen L, Li H, Int. Immunopharmacol., 67, 160 (2019)

[2] Ribas A, Butterfield LH, Glaspy JA, Economou JS, J. Clin. Oncol., 21, 2415 (2003)

[3] Smith DM, Simon JK, Baker JR, Nat. Rev. Immunol., 13, 592 (2013)

[4] Hayat SMG, Darroudi M, J. Cell. Physiol., 234, 12530 (2019)

[5] Huang C, Chen S, Zhang T, Li D, Huang Z, Huang J, Qin Y, Chen B, Cheng G, Ma F, Zhou M, Front. Immunol., 10, 1 (2019)

[6] Duluc D, Tan F, Scotet M, Blanchard S, Fremaux I, Garo E, Horvat B, Eid P, Delneste Y, Jeannin P, Eur. J. Immunol., 39, 2877 (2009)

[7] Li Y, Xu XL, Zhao D, Pan LN, Huang CW, Guo LG, Lu Q, Wang J, CNS Neurosci. Ther., 21, 905 (2015)

[8] Zong C, Sun Y, Zhang N, Wang F, Li A, Li Q, Lyu Z, Macromol. Res., 27(8), 772 (2019)

[9] Correia-Pinto JF, Csaba N, Schiller JT, Alonso MJ, Vaccines, 3, 730 (2015)

[10] Phil L, Naveed M, Mohammad IS, Bo L, Bin D, Biomed. Pharmacother., 012, 438 (2018)

[11] Kim SK, Park PJ, Yang HP, Han SS, Arzneimittel-Forschung, 51, 769 (2001)

[12] Yang EJ, Kim JG, Kim JY, Kim SC, Lee NH, Hyun CG, Cent. Eur. J. Biol., 5, 95 (2010)

[13] Huang X, Chen M, Wu H, Jiao Y, Zhou C, ACS Biomater. Sci. Eng., 6, 1614 (2020)

[14] Chung MJ, Park JK, Park YI, Int. Immunopharmacol., 12, 453 (2012)

[15] Su LY, Fang TY, Tseng WC, Biochem. Eng. J., 49, 21 (2010)

[16] Ahn HH, Lee JH, Kim KS, Lee JY, Kim MS, Khang G, Lee IW, Lee HB, Biomaterials, 29, 2415 (2008)

[17] Park H, Nichols JW, Kang HC, Bae YH, Polym. Adv. Technol., 25, 545 (2014)

[18] Duo X, Bai L, Wang J, Ji H, Guo J, Ren X, Shi C, Xia S, Zhang W, Feng Y, Polym. Adv. Technol., 30, 2567 (2019)

[19] Gao JQ, Zhao QQ, Lv TF, Shuai WP, Zhou J, Tang GP, Liang WQ, Tabata Y, Hu YL, Int. J. Pharm., 387, 286 (2010)

[20] Bao X, Wang W, Wang C, Wang Y, Zhou J, Ding Y, Biomaterials, 35, 8450 (2014)

[21] Sugiura H, Okazaki N, Sugiura T, Honda H, Okochi M, Biochem. Eng. J., 87, 8 (2014)

[22] Liu K, Chen S, Chen H, Tong P, Gao J, Int. J. Biol. Macromol., 107, 2057 (2018)

[23] Li Z, Kuang H, Yang J, Hu J, Ding B, Sun W, Luo Y, Sci. Rep., 10, 1 (2020)

[24] Chuck AS, Clarke MF, Palsson BO, Gene Therapy, 1534, 1527 (1996)

[25] Liu Y, Tan J, Thomas A, Ou-Yang D, Muzykantov VR, Ther. Deliv., 3, 181 (2012)

[26] Li Y, Lian Y, Zhang LT, Aldousari SM, Hedia HS, Asiri SA, Liu WK, Interface Focus, 6, 0086 (2015)

[27] Torchilin VP, Nat. Rev. Drug Discov., 4, 145 (2005)

[28] Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH, Int. J. Mol. Sci., 22, 1 (2021)

[29] Lee CC, Chiu CC, Liao WT, Wu PF, Chen YT, Huang KC, Chou YT, Wen ZH, Wang HM, Biochem. Eng. J., 78, 101 (2013)